Abstract
Patients diagnosed with craniopharyngioma often experience rapid and pronounced weight gain that can progress to severe hypothalamic obesity. This phenomenon is predominantly attributed to disruption of critical hypothalamic regulatory circuits, caused either by direct tumor infiltration or by treatment-related injury. Hypothalamic obesity is best conceptualized within the broader framework of hypothalamic syndrome, a complex clinical disorder encompassing multiple neuroendocrine deficits, impairments in circadian homeostasis, dysregulation of hunger, satiety, and thirst mechanisms, disturbances in thermoregulatory control, and a wide range of cognitive, sleep-related, and psychosocial abnormalities. Hypothalamic syndrome may also develop secondary to nonmalignant parasellar pathologies, including germ cell tumors, gliomas, Rathke’s cleft cyst, and Langerhans cell histiocytosis, as well as traumatic hypothalamic injury following traumatic brain insult. Long-term prognosis is frequently poor, driven by elevated risks of metabolic syndrome, cardiovascular disease, diminished health-related quality of life, and increased rates of premature mortality. Management remains particularly challenging. Recently, a personalized and risk-stratified therapeutic framework has been proposed to guide clinical decision-making and optimize outcomes. Several pharmacologic interventions, such as centrally acting stimulants, glucagon-like peptide-1 receptor agonists, and the melanocortin-4 receptor agonist setmelanotide, have demonstrated potential in promoting weight reduction. Bariatric surgery may also yield clinical benefit; however, the use of irreversible procedures in pediatric populations presents substantial ethical and legal challenges. There remains an urgent need for therapeutic strategies that emphasize preservation of hypothalamic structure and function, alongside continued research into targeted and emerging interventions for more effective management of hypothalamic syndrome.
Keywords: Craniopharyngioma, obesity, metabolic syndrome, quality of life, hypothalamus, sequelae
Read the full text
2 sections · 2 figures · 2 tables · PDF
Create your free account to read the full text.
- Full text with figures and tables
- PDF and supplementary files
- Access on every Galenos journal
One Galenos account works on every Galenos journal site.
References
Müller HL. Management of Acquired Hypothalamic Obesity After Childhood-Onset Craniopharyngioma-A Narrative Review. Biomedicines. 2025;13:1016.
Müller HL. Craniopharyngioma. Endocr Rev. 2014;35:513-543. Epub 2014 Jan 27
Witte J, Surmann B, Batram M, Weinert M, Flume M, Touchot N, Beckhaus J, Friedrich C, Müller HL. Hypothalamic obesity: Epidemiology in rare sellar/suprasellar tumors-A German claims database analysis. J Neuroendocrinol. 2024;36:e13439. Epub 2024 Aug 27
Santagata S, Kleinschmidt-DeMasters BK, Komori T, Müller HL, Pietsch T. Adamantinomatous craniopharyngioma. In: Brat DJ GA, Wesseling P (eds) Tumours of the sellar region), editor. WHO Classification of Tumours Editorial Board Central nervous system tumours. WHO classification of tumours series. 6. 5th ed. Lyon (France), International Agency for Research on Cancer, 2021;393-396.
Apps JR, Muller HL, Hankinson TC, Yock TI, Martinez-Barbera JP. Contemporary Biological Insights and Clinical Management of Craniopharyngioma. Endocr Rev. 2023;44:518-538.
Pereira AM, Schmid EM, Schutte PJ, Voormolen JH, Biermasz NR, van Thiel SW, Corssmit EP, Smit JW, Roelfsema F, Romijn JA. High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clin Endocrinol (Oxf). 2005;62:197-204.
Müller HL, Bueb K, Bartels U, Roth C, Harz K, Graf N, Korinthenberg R, Bettendorf M, Kühl J, Gutjahr P, Sörensen N, Calaminus G. Obesity after childhood craniopharyngioma--German multicenter study on pre-operative risk factors and quality of life. Klin Padiatr. 2001;213:244-249.
Poretti A, Grotzer MA, Ribi K, Schönle E, Boltshauser E. Outcome of craniopharyngioma in children: long-term complications and quality of life. Dev Med Child Neurol. 2004;46:220-229.
Hoffmann A, Bootsveld K, Gebhardt U, Daubenbüchel AM, Sterkenburg AS, Müller HL. Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma. Eur J Endocrinol. 2015;173:389-397. Epub 2015 Jun 18
Erfurth EM, Holmer H, Fjalldal SB. Mortality and morbidity in adult craniopharyngioma. Pituitary. 2013;16:46-55.
Daubenbüchel AM, Hoffmann A, Gebhardt U, Warmuth-Metz M, Sterkenburg AS, Müller HL. Hydrocephalus and hypothalamic involvement in pediatric patients with craniopharyngioma or cysts of Rathke’s pouch: impact on long-term prognosis. Eur J Endocrinol. 2015;172:561-569. Epub 2015 Feb 3
Sterkenburg AS, Hoffmann A, Gebhardt U, Warmuth-Metz M, Daubenbüchel AM, Müller HL. Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes. Neuro Oncol. 2015;17:1029-1038. Epub 2015 Apr 2
Harz KJ, Müller HL, Waldeck E, Pudel V, Roth C. Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity. J Clin Endocrinol Metab. 2003;88:5227-5231.
Hoffmann A, Gebhardt U, Sterkenburg AS, Warmuth-Metz M, Müller HL. Diencephalic syndrome in childhood craniopharyngioma--results of German multicenter studies on 485 long-term survivors of childhood craniopharyngioma. J Clin Endocrinol Metab. 2014;99:3972-3977. Epub 2014 Jul 31
Mann-Markutzyk LV, Beckhaus J, Özyurt J, Mehren A, Friedrich C, Müller HL. Daytime sleepiness and health-related quality of life in patients with childhood-onset craniopharyngioma. Sci Rep. 2025;15:9407.
Müller HL. Increased daytime sleepiness in patients with childhood craniopharyngioma and hypothalamic tumor involvement: review of the literature and perspectives. Int J Endocrinol. 2010;2010:519607. Epub 2010 Dec 16
Holmer H, Pozarek G, Wirfält E, Popovic V, Ekman B, Björk J, Erfurth EM. Reduced energy expenditure and impaired feeding-related signals but not high energy intake reinforces hypothalamic obesity in adults with childhood onset craniopharyngioma. J Clin Endocrinol Metab. 2010;95:5395-5402. Epub 2010 Sep 8
Özyurt J, Thiel CM, Lorenzen A, Gebhardt U, Calaminus G, Warmuth-Metz M, Müller HL. Neuropsychological outcome in patients with childhood craniopharyngioma and hypothalamic involvement. J Pediatr. 2014;164:876-881. Epub 2014 Feb 6
Witte J, Touchot N, Batram M, Diekmannshemke J, Flume M, Müller HL. Epidemiology of acquired hypothalamic obesity following traumatic brain injury and nonspecific hypothalamic microinjury: A nationwide German claims data analysis. J Neuroendocrinol. 2025:e70108. Epub 2025 Nov 14
van Santen HM, van Schaik J, van Roessel IMAA, Beckhaus J, Boekhoff S, Müller HL. Diagnostic criteria for the hypothalamic syndrome in childhood. Eur J Endocrinol. 2023;188:Iva009.
van Iersel L, Brokke KE, Adan RAH, Bulthuis LCM, van den Akker ELT, van Santen HM. Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review. Endocr Rev. 2019;40:193-235.
van Santen HM, Müller HL. Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity. Endocr Rev. 2025;46:891-907.
Doelman-Oldenburger NJ, Müller HL, van Santen HM. Novel autonomic dysregulation score in children with hypothalamic syndrome. Endocr Connect. 2025;14:e250336.
Müller HL, Gebhardt U, Teske C, Faldum A, Zwiener I, Warmuth-Metz M, Pietsch T, Pohl F, Sörensen N, Calaminus G; Study Committee of KRANIOPHARYNGEOM 2000. Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. Eur J Endocrinol. 2011;165:17-24. Epub 2011 Apr 13
Müller HL, Gebhardt U, Faldum A, Warmuth-Metz M, Pietsch T, Pohl F, Calaminus G, Sörensen N; Kraniopharyngeom 2000 Study Committee. Xanthogranuloma, Rathke’s cyst, and childhood craniopharyngioma: results of prospective multinational studies of children and adolescents with rare sellar malformations. J Clin Endocrinol Metab. 2012;97:3935-3943. Epub 2012 Sep 11
Van Schaik J, Schouten-van Meeteren AYN, Vos-Kerkhof E, Janssens GO, Porro GL, Fiocco M, Bakker B, Tissing WJE, Hoving EW, van Santen HM. Treatment and outcome of the Dutch Childhood Craniopharyngioma Cohort study: First results after centralization of care. Neuro Oncol. 2023;25:2250-2261.
Sterkenburg AS, Hoffmann A, Gebhardt U, Warmuth-Metz M, Daubenbüchel AM, Müller HL. Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes. Neuro Oncol. 2015;17:1029-1038. Epub 2015 Apr 2
Boguszewski MCS, Boguszewski CL, Chemaitilly W, Cohen LE, Gebauer J, Higham C, Hoffman AR, Polak M, Yuen KCJ, Alos N, Antal Z, Bidlingmaier M, Biller BMK, Brabant G, Choong CSY, Cianfarani S, Clayton PE, Coutant R, Cardoso-Demartini AA, Fernandez A, Grimberg A, Guðmundsson K, Guevara-Aguirre J, Ho KKY, Horikawa R, Isidori AM, Jørgensen JOL, Kamenicky P, Karavitaki N, Kopchick JJ, Lodish M, Luo X, McCormack AI, Meacham L, Melmed S, Mostoufi Moab S, Müller HL, Neggers SJCMM, Aguiar Oliveira MH, Ozono K, Pennisi PA, Popovic V, Radovick S, Savendahl L, Touraine P, van Santen HM, Johannsson G. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. Eur J Endocrinol. 2022;186:P35-P52.
Heinks K, Boekhoff S, Hoffmann A, Warmuth-Metz M, Eveslage M, Peng J, Calaminus G, Müller HL. Quality of life and growth after childhood craniopharyngioma: results of the multinational trial KRANIOPHARYNGEOM 2007. Endocrine. 2018;59:364-372. Epub 2017 Dec 11
Müller HL, Heinrich M, Bueb K, Etavard-Gorris N, Gebhardt U, Kolb R, Sörensen N. Perioperative dexamethasone treatment in childhood craniopharyngioma--influence on short-term and long-term weight gain. Exp Clin Endocrinol Diabetes. 2003;111:330-334.
van Iersel L, Xu J, Potter BS, Conklin HM, Zhang H, Chemaitilly W, van Santen HM, Merchant TE. Clinical Importance of Free Thyroxine Concentration Decline After Radiotherapy for Pediatric and Adolescent Brain Tumors. J Clin Endocrinol Metab. 2019;104:4998-5007.
Sowithayasakul P, Boekhoff S, Bison B, Müller HL. Pregnancies after Childhood Craniopharyngioma: Results of KRANIOPHARYNGEOM 2000/2007 and Review of the Literature. Neuroendocrinology. 2021;111:16-26. Epub 2020 Feb 20
Daubenbüchel AM, Özyurt J, Boekhoff S, Warmuth-Metz M, Eveslage M, Müller HL. Eating behaviour and oxytocin in patients with childhood-onset craniopharyngioma and different grades of hypothalamic involvement. Pediatr Obes. 2019;14:e12527. Epub 2019 Apr 23
Daubenbüchel AM, Hoffmann A, Eveslage M, Özyurt J, Lohle K, Reichel J, Thiel CM, Martens H, Geenen V, Müller HL. Oxytocin in survivors of childhood-onset craniopharyngioma. Endocrine. 2016;54:524-531. Epub 2016 Sep 1
Hoffmann A, Özyurt J, Lohle K, Reichel J, Thiel CM, Müller HL. First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma. Endocrine. 2017;56:175-185. Epub 2017 Feb 17
Özyurt J, Mehren A, Boekhoff S, Müller HL, Thiel CM. Social Cognition in Patients With Hypothalamic-Pituitary Tumors. Front Oncol. 2020;10:1014.
Müller HL. Management of Hypothalamic Obesity. Endocrinol Metab Clin North Am. 2020;49:533-552. Epub 2020 Jul 15
Lin B, Xiang S, Chen J, Jing Y, Ye Z, Zhang Y, Cao X, Yin Z, Qiao N, Zhou X. Assessment of quality of life in patients with craniopharyngioma and identification of risk factors for compromised overall wellness. Arch Endocrinol Metab. 2023;68:e230001.
Müller HL, Müller-Stöver S, Gebhardt U, Kolb R, Sörensen N, Handwerker G. Secondary narcolepsy may be a causative factor of increased daytime sleepiness in obese childhood craniopharyngioma patients. J Pediatr Endocrinol Metab. 2006;19(Suppl 1):423-429.
Romigi A, Feola T, Cappellano S, De Angelis M, Pio G, Caccamo M, Testa F, Vitrani G, Centonze D, Colonnese C, Esposito V, Jaffrain-Rea ML. Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update. Front Neurol. 2021;12:817257.
Tran LT, Park S, Kim SK, Lee JS, Kim KW, Kwon O. Hypothalamic control of energy expenditure and thermogenesis. Exp Mol Med. 2022;54:358-369. Epub 2022 Mar 17
Müller HL, Tauber M, Lawson EA, Özyurt J, Bison B, Martinez-Barbera JP, Puget S, Merchant TE, van Santen HM. Hypothalamic syndrome. Nat Rev Dis Primers. 2022;8:24.
van Roessel IMAA, Hulsmann SC, Schouten-van Meeteren AYN, Hoving EW, Janssens GO, Raphael MF, Zijtregtop-Blom EAM, de Vos-Kerkhof E, Bakker B, Tissing WJE, van Santen HM. The many different clinical faces of acquired hypothalamic dysfunction: a retrospective cohort study in the Netherlands. EClinicalMedicine. 2025;85:103313.
Mehren A, Özyurt J, Zu Klampen P, Boekhoff S, Thiel CM, Müller HL. Self- and informant-rated apathy in patients with childhood-onset craniopharyngioma. J Neurooncol. 2018;140:27-35. Epub 2018 Jul 3
Özyurt J, Müller HL, Thiel CM. A systematic review of cognitive performance in patients with childhood craniopharyngioma. J Neurooncol. 2015;125:9-21. Epub 2015 Sep
Müller HL, Emser A, Faldum A, Bruhnken G, Etavard-Gorris N, Gebhardt U, Oeverink R, Kolb R, Sörensen N. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. J Clin Endocrinol Metab. 2004;89:3298-3305.
Fjalldal S, Holmer H, Rylander L, Elfving M, Ekman B, Osterberg K, Erfurth EM. Hypothalamic involvement predicts cognitive performance and psychosocial health in long-term survivors of childhood craniopharyngioma. J Clin Endocrinol Metab. 2013;98:3253-3262. Epub 2013 Jun 14
Müller HL, Faldum A, Etavard-Gorris N, Gebhardt U, Oeverink R, Kolb R, Sörensen N. Functional capacity, obesity and hypothalamic involvement: cross-sectional study on 212 patients with childhood craniopharyngioma. Klin Padiatr. 2003;215:310-314.
Müller HL, Bruhnken G, Emser A, Faldum A, Etavard-Gorris N, Gebhardt U, Kolb R, Sörensen N. Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma. Childs Nerv Syst. 2005;21:975-980. Epub 2005 Jun 18
Müller HL, Gebhardt U, Faldum A, Emser A, Etavard-Gorris N, Kolb R, Sörensen N. Functional capacity and body mass index in patients with sellar masses--cross-sectional study on 403 patients diagnosed during childhood and adolescence. Childs Nerv Syst. 2005;21:539-545. Epub 2005 May 12
Ondruch A, Maryniak A, Kropiwnicki T, Roszkowski M, Daszkiewicz P. Cognitive and social functioning in children and adolescents after the removal of craniopharyngioma. Childs Nerv Syst. 2011;27:391-397. Epub 2010 Oct 8
Crom DB, Smith D, Xiong Z, Onar A, Hudson MM, Merchant TE, Morris EB. Health status in long-term survivors of pediatric craniopharyngiomas. J Neurosci Nurs. 2010;42:329-330.
Ozyurt J, Lorenzen A, Gebhardt U, Warmuth-Metz M, Müller HL, Thiel CM. Remote effects of hypothalamic lesions in the prefrontal cortex of craniopharygioma patients. Neurobiol Learn Mem. 2014;111:71-80. Epub 2014 Mar 22
Fjalldal S, Follin C, Svärd D, Rylander L, Gabery S, Petersén Å, van Westen D, Sundgren PC, Björkman-Burtscher IM, Lätt J, Ekman B, Johanson A, Erfurth EM. Microstructural white matter alterations and hippocampal volumes are associated with cognitive deficits in craniopharyngioma. Eur J Endocrinol. 2018;178:577-587. Epub 2018 Mar 29
Dekkers OM, Biermasz NR, Smit JW, Groot LE, Roelfsema F, Romijn JA, Pereira AM. Quality of life in treated adult craniopharyngioma patients. Eur J Endocrinol. 2006;154:483-489.
Hammond JL, Hall SS. Functional analysis and treatment of aggressive behavior following resection of a craniopharyngioma. Dev Med Child Neurol. 2011;53:369-374. Epub 2011 Jan 14
Beckhaus J, Friedrich C, Boekhoff S, Calaminus G, Bison B, Eveslage M, Timmermann B, Flitsch J, Müller HL. Outcome after pediatric craniopharyngioma: the role of age at diagnosis and hypothalamic damage. Eur J Endocrinol. 2023;188:Ivad027.
Gan HW, Cerbone M, Dattani MT. Appetite- and Weight-Regulating Neuroendocrine Circuitry in Hypothalamic Obesity. Endocr Rev. 2024;45:309-342.
Van Schaik J, Burghard M, Lequin MH, van Maren EA, van Dijk AM, Takken T, Rehorst-Kleinlugtenbelt LB, Bakker B, Meijer L, Hoving EW, Fiocco M, Schouten-van Meeteren AYN, Tissing WJE, van Santen HM. Resting energy expenditure in children at risk of hypothalamic dysfunction. Endocr Connect. 2022;11:e220276.
Müller HL, Handwerker G, Gebhardt U, Faldum A, Emser A, Kolb R, Sörensen N. Melatonin treatment in obese patients with childhood craniopharyngioma and increased daytime sleepiness. Cancer Causes Control. 2006;17:583-589.
Müller HL, Handwerker G, Wollny B, Faldum A, Sörensen N. Melatonin secretion and increased daytime sleepiness in childhood craniopharyngioma patients. J Clin Endocrinol Metab. 2002;87:3993-3996.
Denzer C, Denzer F, Lennerz BS, Vollbach H, Lustig RH, Wabitsch M. Treatment of Hypothalamic Obesity with Dextroamphetamine: A Case Series. Obes Facts. 2019;12:91-102. Epub 2019 Mar 7
van Schaik J, Welling MS, de Groot CJ, van Eck JP, Juriaans A, Burghard M, Oude Ophuis SBJ, Bakker B, Tissing WJE, Schouten-van Meeteren AYN, van den Akker ELT, van Santen HM. Dextroamphetamine Treatment in Children With Hypothalamic Obesity. Front Endocrinol (Lausanne). 2022;13:845937.
Müller HL, Tanaka T, Hasegawa T, Isojima T, Mori J, Kurosaki M, Nishioka H, Choi HJ, Hong AR, Kim JH, Arima H. Diagnostic criteria for acquired hypothalamic obesity - international expert guidance document. Endocr J. 2026;73:341-353. Epub 2025 Nov 11
Hoffmann A, Postma FP, Sterkenburg AS, Gebhardt U, Müller HL. Eating behavior, weight problems and eating disorders in 101 long-term survivors of childhood-onset craniopharyngioma. J Pediatr Endocrinol Metab. 2015;28:35-43.
Rovani S, Butler V, Samara-Boustani D, Pinto G, Gonzalez-Briceno L, Nguyen Quoc A, Vermillac G, Stoupa A, Besançon A, Beltrand J, Thalassinos C, Flechtner I, Dassa Y, Viaud M, Arrom-Branas MB, Boddaert N, Puget S, Blauwblomme T, Alapetite C, Bolle S, Doz F, Grill J, Dufour C, Bourdeaut F, Abbou S, Guerrini-Rousseau L, Leruste A, Beccaria K, Polak M, Kariyawasam D. Long-term weight gain in children with craniopharyngioma. Eur J Endocrinol. 2024;190:363-373.
Beckhaus J, Eveslage M, Bison B, Friedrich C, Müller HL. Impact of parental body mass index at diagnosis on obesity in survivors of pediatric craniopharyngioma. Endocr Connect. 2024;13:e240126.
Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, Galanis E. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. N Engl J Med. 2023;389:118-126.
Van Roessel IMAA, Van Den Brink M, Dekker J, Ruitenburg-van Essen BG, Tissing WJE, van Santen HM. Feasibility, safety, and efficacy of dietary or lifestyle interventions for hypothalamic obesity: A systematic review. Clin Nutr. 2024;43:1798-1811. Epub 2024 May 27
Meijneke RW, Schouten-van Meeteren AY, de Boer NY, van Zundert S, van Trotsenburg PA, Stoelinga F, van Santen HM. Hypothalamic obesity after treatment for craniopharyngioma: the importance of the home environment. J Pediatr Endocrinol Metab. 2015;28:59-63.
Hamilton JK, Conwell LS, Syme C, Ahmet A, Jeffery A, Daneman D. Hypothalamic Obesity following Craniopharyngioma Surgery: Results of a Pilot Trial of Combined Diazoxide and Metformin Therapy. Int J Pediatr Endocrinol. 2011;2011:417949. Epub 2011 Mar 22
Kalina MA, Wilczek M, Kalina-Faska B, Skała-Zamorowska E, Mandera M, Małecka Tendera E. Carbohydrate-lipid profile and use of metformin with micronized fenofibrate in reducing metabolic consequences of craniopharyngioma treatment in children: single institution experience. J Pediatr Endocrinol Metab. 2015;28:45-51.
Masarwa R, Brunetti VC, Aloe S, Henderson M, Platt RW, Filion KB. Efficacy and Safety of Metformin for Obesity: A Systematic Review. Pediatrics. 2021;147:e20201610.
Svendstrup M, Rasmussen AK, Kistorp C, Klose M, Andreassen M. Semaglutide treatment of hypothalamic obesity - a real-life data study. Pituitary. 2024;27:685-692. Epub 2024 Aug 9
Ng VWW, Gerard G, Koh JJK, Loke KY, Lee YS, Ng NBH. The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review. Clin Obes. 2024;14:e12642. Epub 2024 Jan 25
Shoemaker AH, Silver HJ, Buchowski M, Slaughter JC, Yanovski JA, Elfers C, Roth CL, Abuzzahab MJ. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist. Int J Obes (Lond). 2022;46:623-629. Epub 2022 Jan 3
Perez FA, Elfers C, Yanovski JA, Shoemaker AH, Abuzzahab MJ, Roth CL. MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity. Diabetes Obes Metab. 2021;23:1532-1541. Epub 2021 Mar 29
Zoicas F, Droste M, Mayr B, Buchfelder M, Schöfl C. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur J Endocrinol. 2013;168:699-706.
Roth CL, Perez FA, Whitlock KB, Elfers C, Yanovski JA, Shoemaker AH, Abuzzahab MJ. A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity. Diabetes Obes Metab. 2021;23:363-373. Epub 2020 Oct 25
Wabitsch M, Farooqi S, Flück CE, Bratina N, Mallya UG, Stewart M, Garrison J, van den Akker E, Kühnen P. Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide. J Endocr Soc. 2022;6:bvac057.
Roth CL, Scimia C, Shoemaker AH, Gottschalk M, Miller J, Yuan G, Malhotra S, Abuzzahab MJ. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024;12:380-389. Epub 2024 Apr 30
https://ir.rhythmtx.com/news-releases/news-release-details/rhythmpharmaceuticals-announces-pivotal-phase-3-transcend-trial
van Santen HM, Denzer C, Müller HL. Could setmelanotide be the game-changer for acquired hypothalamic obesity? Front Endocrinol (Lausanne). 2024;14:1307889.
Roth CL, Hunneman DH, Gebhardt U, Stoffel-Wagner B, Reinehr T, Müller HL. Reduced sympathetic metabolites in urine of obese patients with craniopharyngioma. Pediatr Res. 2007;61:496-501.
Elfers CT, Roth CL. Effects of methylphenidate on weight gain and food intake in hypothalamic obesity. Front Endocrinol (Lausanne). 2011;2:78.
Mason PW, Krawiecki N, Meacham LR. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch Pediatr Adolesc Med. 2002;156:887-892.
Hsia DS, Gosselin NH, Williams J, Farhat N, Marier JF, Shih W, Peterson C, Siegel R. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity. Diabetes Obes Metab. 2020;22:480-491. Epub 2019 Dec 18
Huynh K, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S, Magkos F, Aharaz A, Edsberg B, Tfelt-Hansen J, Astrup AV, Feldt-Rasmussen U. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022;186:687-700.
Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, Rai SN, Lensing SY, Wu S, Xiong X. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88:2586-2592.
Hsu EA, Miller JL, Perez FA, Roth CL. Oxytocin and Naltrexone Successfully Treat Hypothalamic Obesity in a Boy Post-Craniopharyngioma Resection. J Clin Endocrinol Metab. 2018;103:370-375.
Bretault M, Boillot A, Muzard L, Poitou C, Oppert JM, Barsamian C, Gatta B, Müller H, Weismann D, Rottembourg D, Inge T, Veyrie N, Carette C, Czernichow S. Clinical review: Bariatric surgery following treatment for craniopharyngioma: a systematic review and individual-level data meta-analysis. J Clin Endocrinol Metab. 2013;98:2239-2246. Epub 2013 Mar 26
Müller HL. Bariatric Interventions in Craniopharyngioma Patients-Best Choice or Last Option for Treatment of Hypothalamic Obesity? J Clin Endocrinol Metab. 2022;107:e426-e428.
Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, Yanovski JA. Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102:709-757.
Eveslage M, Calaminus G, Warmuth-Metz M, Kortmann RD, Pohl F, Timmermann B, Schuhmann MU, Flitsch J, Faldum A, Müller HL. The Postopera tive Quality of Life in Children and Adolescents with Craniopharyngioma. Dtsch Arztebl Int. 2019;116:321-328.
Bogusz A, Boekhoff S, Warmuth-Metz M, Calaminus G, Eveslage M, Müller HL. Posterior hypothalamus-sparing surgery improves outcome after childhood craniopharyngioma. Endocr Connect. 2019;8:481-492.
Müller HL. Paediatrics: surgical strategy and quality of life in craniopharyngioma. Nat Rev Endocrinol. 2013;9:447-449. Epub 2013 Jun 25
Müller HL, Reichel J, Boekhoff S, Warmuth-Metz M, Eveslage M, Peng J, Flitsch J. Low concordance between surgical and radiological assessment of degree of resection and treatment-related hypothalamic damage: results of KRANIOPHARYNGEOM 2007. Pituitary. 2018;21:371-378.
Müller HL. Craniopharyngioma - What’s next. Pituitary. 2025;28:125.
van Roessel IMAA, de Graaf JP, Biermasz NR, Charmandari E, van Santen HM. Acquired hypothalamic dysfunction in childhood: ‘what do patients need?’ - an Endo-ERN survey. Endocr Connect. 2023;12:e230147.
Niel KA, Klages KL, Merchant TE, Wise MS, Hancock D, Caples M, Mandrell BN, Conklin HM, Crabtree VM. Impact of sleep, neuroendocrine, and executive function on health-related quality of life in young people with craniopharyngioma. Dev Med Child Neurol. 2021;63:984-990. Epub 2021 Mar 22
Craven M, Crowley JH, Chiang L, Kline C, Malbari F, Hocking MC, McCormack SE. A Survey of Patient-Relevant Outcomes in Pediatric Craniopharyngioma: Focus on Hypothalamic Obesity. Front Endocrinol (Lausanne). 2022;13:876770.
Aldave G, Okcu MF, Chintagumpala M, Ruggieri L, Minard CG, Malbari F, Mash LE, Paulino AC, McGovern S, Ramaswamy U, Whitehead W, Kahalley LS. Comparison of neurocognitive and quality-of-life outcomes in pediatric craniopharyngioma patients treated with partial resection and radiotherapy versus gross-total resection only. J Neurosurg Pediatr. 2023;31:453-462.
Kayadjanian N, Hsu EA, Wood AM, Carson DS. Caregiver Burden and Its Relationship to Health-Related Quality of Life in Craniopharyngioma Survivors. J Clin Endocrinol Metab. 2023;109:e76-e87.
Sowithayasakul P, Beckhaus J, Boekhoff S, Friedrich C, Calaminus G, Müller HL. Vision-related quality of life in patients with childhood-onset craniopharyngioma. Sci Rep. 2023;13:19599.
Friedrich C, Boekhoff S, Bischoff M, Beckhaus J, Sowithayasakul P, Calaminus G, Eveslage M, Valentini C, Bison B, Harrabi SB, Krause M, Timmermann B, Müller HL. Outcome after proton beam therapy versus photon-based radiation therapy in childhood-onset craniopharyngioma patients-results of KRANIOPHARYNGEOM 2007. Front Oncol. 2023;13:1180993.
Baqai MWS, Shah Z, Malik MJA, Zia N, Shafqat S, Zahid N, Shamim MS. Quality of life of pediatric patients with craniopharyngioma: A retrospective series from a low-middle-income country with more than 4 years follow-up. Surg Neurol Int. 2024;15:199.
Mandrell BN, Guo Y, Li Y, Hancock D, Caples M, Ashford JM, Merchant TE, Conklin HM, Crabtree VM. Internalizing Symptoms and Their Impact on Patient-Reported Health-Related Quality of Life and Fatigue among Patients with Craniopharyngioma During Proton Radiation Therapy. Children (Basel). 2024;11:1159.
Pereira Neto B, Pais Cunha I, Leite-Almeida AL, Ferreira S, Coelho J, Lago R, Pereira J, Gil-da-Costa MJ, Almeida P, Castro-Correia C. Quality of Life and Hormonal Impairment in Pediatric Patients With Craniopharyngiomas. Cureus. 2024;16:e52621.
Pérez-Torres Lobato MR, Morell M, Solano-Páez P, Ortiz-Palacios M, Menárgez Á, Panesso M, Vázquez-Gómez F, Moreno-Carrasco J, Lassaletta Á, Santa-María V, Pavon-Mengual M, Quiroga E, García-Ariza MA, Mora-Matilla M, Garrido-Colino C, Verdú-Amoros J, Nova-Lozano C, Vieito M, Cordero-Asanza EX, Clemente M, Ramos-Albiat M, de Las Morenas-Iglesias J, Moreno L, Llort A. Long-term sequelae and quality of life after childhood-onset craniopharyngioma: Results of a Spanish multicenter study. Pediatr Blood Cancer. 2024;71:e31343.
Rose ML, Bajaj BVM, Jimenez R, Dennehy S, Allison K, Wiltsie L, Ebb D, MacDonald SM, Tarbell NJ, Yock TI. Quality of life in pediatric patients treated with adjuvant proton radiation for craniopharyngiomas. J Neurooncol. 2025;175:153-164. Epub 2025 Jun 18
Hamilton JK, Conwell LS, Syme C, Ahmet A, Jeffery A, Daneman D. Hypothalamic Obesity following Craniopharyngioma Surgery: Results of a Pilot Trial of Combined Diazoxide and Metformin Therapy. Int J Pediatr Endocrinol. 2011;2011:417949. Epub 2011 Mar 22
Gjersdal E, Larsen LB, Ettrup KS, Vestergaard P, Nielsen EH, Karmisholt JS, Müller HL, Dal J. Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma. Pituitary. 2024;27:723-730. Epub 2024 Aug 1
Lomenick JP, Buchowski MS, Shoemaker AH. A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity. Obesity (Silver Spring). 2016;24:1222-1225. Epub 2016 May 2
Rakhshani N, Jeffery AS, Schulte F, Barrera M, Atenafu EG, Hamilton JK. Evaluation of a comprehensive care clinic model for children with brain tumor and risk for hypothalamic obesity. Obesity (Silver Spring). 2010;18:1768-1774. Epub 2010 Jan 7
Wijnen M, Olsson DS, van den Heuvel-Eibrink MM, Wallenius V, Janssen JA, Delhanty PJ, van der Lely AJ, Johannsson G, Neggers SJ. Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case-control study with 2 years of follow-up. Int J Obes (Lond). 2017;41:210-216. Epub 2016 Oct 31
Müller HL, Gebhardt U, Maroske J, Hanisch E. Long-term follow-up of morbidly obese patients with childhood craniopharyngioma after laparoscopic adjustable gastric banding (LAGB). Klin Padiatr. 2011;223:372-373. Epub 2011 Nov 3
Müller HL, Gebhardt U, Wessel V, Schröder S, Kolb R, Sörensen N, Maroske J, Hanisch E. First experiences with laparoscopic adjustable gastric banding (LAGB) in the treatment of patients with childhood craniopharyngioma and morbid obesity. Klin Padiatr. 2007;219:323-325.
Gatta B, Nunes ML, Bailacq-Auder C, Etchechoury L, Collet D, Tabarin A. Is bariatric surgery really inefficient in hypothalamic obesity? Clin Endocrinol (Oxf). 2013;78:636-638.
Weismann D, Pelka T, Bender G, Jurowich C, Fassnacht M, Thalheimer A, Allolio B. Bariatric surgery for morbid obesity in craniopharyngioma. Clin Endocrinol (Oxf). 2013;78:385-390.
Trotta M, Da Broi J, Salerno A, Testa RM, Marinari GM. Sleeve gastrectomy leads to easy management of hormone replacement therapy and good weight loss in patients treated for craniopharyngioma. Updates Surg. 2017;69:95-99. Epub 2017 Mar 4
Garrez I, Lapauw B, Van Nieuwenhove Y. Bariatric Surgery for Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy: a Matched Case-Control Study. Obes Surg. 2020;30:2439-2444.
van Santen SS, Wolf P, Kremenevski N, Boguszewski CL, Beiglböck H, Fiocco M, Wijnen M, Wallenius VR, van den Heuvel-Eibrink MM, van der Lely AJ, Johannsson G, Luger A, Krebs M, Buchfelder M, Delhanty PJD, Neggers SJCMM, Olsson DS. Bariatric Surgery for Hypothalamic Obesity in Craniopharyngioma Patients: A Retrospective, Matched Case-Control Study. J Clin Endocrinol Metab. 2021;106:e4734-e4745.
Faucher P, Carette C, Jannot AS, Gatta-Cherifi B, Van Straaten A, Piquet MA, Raverot G, Alligier M, Batisse T, Ziegler O, Drui D, Bretault M, Farigon N, Slim K, Genser L, Poghosyan T, Vychnevskaia K, Blanchard C, Robert M, Gronnier C, Poitou C, Czernichow S. Five-Year Changes in Weight and Diabetes Status After Bariatric Surgery for Craniopharyngioma-Related Hypothalamic Obesity: a Case-Control Study. Obes Surg. 2022;32:2321-2331. Epub 2022 May 6
Smith DK, Sarfeh J, Howard L. Truncal vagotomy in hypothalamic obesity. Lancet. 1983;1:1330-1331.
Harat M, Rudaś M, Zieliński P, Birska J, Sokal P. Nucleus accumbens stimulation in pathological obesity. Neurol Neurochir Pol. 2016;50:207-210. Epub 2016 Feb 5
Puget S, Garnett M, Wray A, Grill J, Habrand JL, Bodaert N, Zerah M, Bezerra M, Renier D, Pierre-Kahn A, Sainte-Rose C. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg. 2007;106(Suppl 1):3-12.
de Vile CJ, Grant DB, Hayward RD, Kendall BE, Neville BG, Stanhope R. Obesity in childhood craniopharyngioma: relation to post-operative hypothalamic damage shown by magnetic resonance imaging. J Clin Endocrinol Metab. 1996;81:2734-2737.
